Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy

Naoshi Nishina; Jun Kikuchi; Misato Hashizume; Keiko Yoshimoto; Hideto Kameda; Tsutomu Takeuchi

doi:10.1136/annrheumdis-2013-204137

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy

Naoshi Nishina, Jun Kikuchi, Misato Hashizume, Keiko Yoshimoto, Hideto Kameda, Tsutomu Takeuchi

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	945-947
Number of pages	3
Journal	Annals of the rheumatic diseases
Volume	73
Issue number	5
DOIs	https://doi.org/10.1136/annrheumdis-2013-204137
Publication status	Published - 2014 May

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1136/annrheumdis-2013-204137

Cite this

Nishina, N., Kikuchi, J., Hashizume, M., Yoshimoto, K., Kameda, H., & Takeuchi, T. (2014). Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy. Annals of the rheumatic diseases, 73(5), 945-947. https://doi.org/10.1136/annrheumdis-2013-204137

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab : Implications for molecular targeted therapy. / Nishina, Naoshi ; Kikuchi, Jun; Hashizume, Misato; Yoshimoto, Keiko; Kameda, Hideto; Takeuchi, Tsutomu.

In: Annals of the rheumatic diseases, Vol. 73, No. 5, 05.2014, p. 945-947.

Research output: Contribution to journal › Letter › peer-review

Nishina, N , Kikuchi, J, Hashizume, M, Yoshimoto, K, Kameda, H & Takeuchi, T 2014, 'Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy', Annals of the rheumatic diseases, vol. 73, no. 5, pp. 945-947. https://doi.org/10.1136/annrheumdis-2013-204137

Nishina, Naoshi ; Kikuchi, Jun ; Hashizume, Misato ; Yoshimoto, Keiko ; Kameda, Hideto ; Takeuchi, Tsutomu. / Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab : Implications for molecular targeted therapy. In: Annals of the rheumatic diseases. 2014 ; Vol. 73, No. 5. pp. 945-947.

@article{07bd85e68e1b4c0e9aa8c409ee675057,

title = "Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: Implications for molecular targeted therapy",

author = "Naoshi Nishina and Jun Kikuchi and Misato Hashizume and Keiko Yoshimoto and Hideto Kameda and Tsutomu Takeuchi",

year = "2014",

month = may,

doi = "10.1136/annrheumdis-2013-204137",

language = "English",

volume = "73",

pages = "945--947",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab

T2 - Implications for molecular targeted therapy

AU - Nishina, Naoshi

AU - Kikuchi, Jun

AU - Hashizume, Misato

AU - Yoshimoto, Keiko

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

PY - 2014/5

Y1 - 2014/5

UR - http://www.scopus.com/inward/record.url?scp=84898003691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898003691&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2013-204137

DO - 10.1136/annrheumdis-2013-204137

M3 - Letter

C2 - 24336338

AN - SCOPUS:84898003691

VL - 73

SP - 945

EP - 947

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -